Aduro BioTech, Inc. (NASDAQ:ADRO) is among the top stocks that may remain in focus today as the company shares are trading 3.76% or 0.07 points lower from last closing price of $1.86, reaching $1.79 at last check. Any clue why there is so much of action in the ADRO stock? The share price has dropped in 2 of the last 5 days and is down -53.38% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -52,356 shares, and in total 215844 shares valued at $386361 were seen changing hands compared with 268200 shares valued at $498852 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the ADRO stock is near its bottom.
Aduro BioTech, Inc. (ADRO) shares have notched a 3-month decline of about -53.38%, but has still tumbled -29.55% year to date. By comparison, the stock sank -73.43% over the past 12 months, while it slipped -43.47% over the 1 month. The company’s market cap is around $148.06M, with its short interest ratio standing at 2.98%.
In the current trading session for ADRO, the stock witnessed two major price actions, it rose to a high of $1.89 and was down as much as $1.75 at one point. The high recorded is very low when compared to their 52-week high which is $1.7. The 52-week high is now at -80.31 distance from current price. Their recent low of $8.99 represents a 4.12% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ADRO is $7, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The stock of Aduro BioTech, Inc. earned $-1.23 per share in the trailing 12 months and has a P/E ratio of -1.46. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 105.27 and lower compared to the sector’s average of 37.46. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ADRO also has P/S multiple of 11.49. This is smaller versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 43.04x.
The company recorded an interesting insider sale transaction by the SVP on May 20, 2019. A Securities and Exchanges Commission filings show that Celeste Ferber sold a total of 2,000 ADRO shares that day for a sum of around $6,420. Aduro BioTech, Inc. (ADRO) insiders have acquired no shares in the stock within the past three months. In total, individual insiders traded 45,284 shares in the business, which makes up 5.947% of 761,470 shares that were traded over a year. In the past 12 months, insiders have purchased 501,897 shares while the seller parted with 259,573 shares.
ADRO‘s last price was down -55.59% as compared to the average trading price of 50 days recorded at $4.03 while enlarging the period to 200 trading days, the average closing price was $3.32. At present, there are 79.6 million in the total number of common shares owned by the public and among those 46.12 million shares have been available to trade. The percentage of shares being held by the company management was 1.1% while institutions stake was 48%. The company has generated negative returns on equity over the last 12 months (-66.5%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the ADRO stock, there is another set of technicals that should be looked into and considered. Its -31.88% decline from moving average of $2.63 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.85 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Aduro BioTech, Inc. — 6 analysts rate the stock as a buy with another 0 rating it strong buy. There are 2 analysts who maintain a hold rating for the stock, with 1 giving it a sell rating. Analysts arrived at a 12-month price target of $8.66 on shares of Aduro BioTech, Inc. (NASDAQ:ADRO), which corresponds to 386.52% upside potential than its current market price of $1.79 and implies potential despite the recent drop in the price. However, their current target price has fallen from $8.66 a month ago and is up handily from the consensus target of $8.575 a quarter ago.
In the last five years, the EPS of the company has been roughly -36.2%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 9%. The revenue of the company has risen at an average annualized rate of about 78.7 over the last five years. The company recently recorded a drop of -40.9%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards ADRO stock. MetLife Investment Advisors LLC added position in the company after it grew 50% or 22,977 shares of its common stock. The hedge fund now owns 34,465 shares worth $61,692, SEC documents show. Metropolitan Life Insurance Co NY shored up assets in the stock as 16616 shares have been purchased, increasing its stake by 50% to 24,924 shares which are currently valued at $44,614. In addition, Morgan Stanley recently reported that it now owns 27,948 shares making a total of $50,027 based on the recent price. This refelects a change of 112.2% in their ownership.